Our Chief Scientific Officer, Carlo Toniatti, has been featured in The Medicine Maker, where he explored how we can catalyse the discovery and development of oncology drugs. In the article, he discusses how to overcome the challenges in developing efficacious…
Our Director of Peptide Chemistry, Elisabetta Bianchi, will be attending and speaking at the 1st International Oligonucleotide and Peptides Conference (IOPC 2019) in Milan from September 17-18. The event will cover important and trending topics at the forefront of oligonucleotide…
Next week our Global Vice President of Sales and Marketing, Heidi Kingdon Jones, and Vice President of North American Business Development, Daniel Conlon, will be attending Discovery on Target in Boston. The conference brings the biopharma industry together to share…
Pomezia, Italy - IRBM today announced the signing of a service and development agreement with The University of Texas MD Anderson Cancer Center. The agreement will focus on the development of therapeutic monoclonal antibodies against a novel immune checkpoint target.…
Our Vice President of North American Business Development, Daniel Conlon, will be at the Boston BD conference on September 10. This invitation-only event brings together Biopharma thought leaders to network and explore insights into the business challenges and opportunities facing…
The latest issue of Chemistry Today features a range of interesting contributions in the field of peptide therapeutics, covering drug discovery processes as well as peptide manufacturing and efficient purification methodologies. Elisabetta Bianchi, Director of Peptide Chemistry at IRBM, was…
The essential amino acid tryptophan and the enzymes that cause its degradation influence the regulation of immune, neuronal and intestinal systems. A recent Nature Drug Discovery paper reviewed the potential of tryptophan metabolites as therapeutic targets in a range of…
Despite the fact that less than 20% of the proteome has enzymatic activity, most drug development efforts have so far focused on identifying enzymatic inhibitors. However, targeting a cell’s proteasomal machinery is now considered an effective area of research. As…
Pomezia, Italy, November 19th 2018 – IRBM, a global contract research organization (CRO), has strengthened its position in neurodegenerative disease research following an extension of its long-standing collaboration with CHDI Foundation, a nonprofit biomedical research organization exclusively dedicated to collaboratively developing therapeutics that substantially improve the lives of those affected by Huntington’s disease (HD).
November 5-7, 2018 Copenhagen, Denmark Come meet IRBM’s delegates in Copenhagen to learn more about how IRBM can support your drug discovery efforts. Drop us a line to request a meeting through our contact form or, when open, the PartneringONE…